Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2019 Jul 11;18(9):1577–1586. doi: 10.1158/1535-7163.MCT-18-1386

Figure 2. Establishment and characterization of Pten−/− and ERG Pten−/− prostate cancer organoids.

Figure 2.

A) Tumors derived from our Ptenlox/lox and ERG Ptenlox/lox GEM models were used to establish prostate cancer organoids (3 clones for each genotype) and characterized in 3-D culture conditions for histology, and immunohistochemistry was performed for ERG and AR. B) Western blotting confirming loss of Pten, activation of PI3K pathway, and ERG over-expression. C) Pten−/− and ERG Pten−/− organoids underwent AR Crispr (3 individual clones for each genotype) and were characterized in 3-D culture conditions for histology, and immunohistochemistry was performed for ERG and AR. D) Western blotting confirming loss of Pten, activation of PI3K pathway, ERG over-expression, and loss of AR following AR Crispr.